Continuous Positive Airway Pressure Ventilation After Acute Ischemic Stroke

NCT ID: NCT00151177

Last Updated: 2010-11-24

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE1/PHASE2

Total Enrollment

100 participants

Study Classification

INTERVENTIONAL

Study Start Date

2005-04-30

Study Completion Date

2008-04-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

More than half of all stroke patients have sleep apneas in the acute phase after stroke. Sleep apneas may be associated with higher degrees of disability three months after stroke due to numerous factors associated with sleep apneas such as persistent hypertension, cardiac arrhythmias, and clotting disorders.

Non-invasive CPAP (continuous positive airway pressure)-therapy may reverse a number of these effects very shortly after initiation. The aim of the study is to test the feasibility of early non-invasive CPAP treatment starting in the first night after stroke onset, and to test its efficacy in a randomized clinical trial.

50 patients with acute ischemic stroke will be enrolled and randomly assigned to standard care PLUS CPAP treatment or standard care only. All patients randomized to the intervention group will receive CPAP therapy for the first three nights after stroke. In the fourth night, a cardiorespiratory polygraphy will be performed in patients and controls. Patients assigned to the intervention group with a respiratory distress index \> 10/h will be treated further on. On admission, day 4, and day 10 after stroke, diffusion weighted MRI imaging will be performed to determine the size of the infarction. The NIHSS score will be used to assess clinical short-term outcome on day 4 and day 10. After three months, the outcome will be determined using the modified Rankin scale.

As CPAP therapy may be more laborious for the provider, the additional work-load will be documented using pre-specified scales.

Primary hypothesis of the study is, that CPAP therapy is feasible in acute stroke patients and that the additional work load will not outweigh the benefits.

Secondary hypothesis is that patients assigned to the treatment group have smaller infarctions on MRI and less neurological deficits at 3 months after stroke.

Patients entering the study will be investigated by transcranial Doppler ultrasound in case they have sufficient temporal bone windows for insonation and no stenosis or occlusions of major brain supplying arteries by the time of investigation that disturb the intracerebral blood flow.

All intracranial arteries will be assessed before treatment, after treatment and on day 8 after the insult.

Screen shots will be taken and will be analysed by dynamic vascular ultrasound (DVA), a new software algorithm developed by NHSi, to investigate microcirculatory information from the flow spectra of the major intracranial arteries.

The data from this post-hoc analysis are compared with the data of the polysomnography and with treatment.

Primary hypothesis in this substudy is that DVA reliably identifies patients with sleep apnea on days one and four after stroke. Secondary hypothesis is that DVA can distinguish between treated patients and controls.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Brain Infarction

Keywords

Explore important study keywords that can help with search, categorization, and topic discovery.

ischemic stroke CPAP ventilation

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

A

treatment with three nights of CPAP ventilation starting the first night of admission

Group Type EXPERIMENTAL

non-invasive continuous positive airway pressure ventilation

Intervention Type DEVICE

CPAP-treatment

Intervention Type DEVICE

night time CPAP-mask ventilation

B

usual Stroke Unit care

Group Type NO_INTERVENTION

CPAP-treatment

Intervention Type DEVICE

night time CPAP-mask ventilation

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

non-invasive continuous positive airway pressure ventilation

Intervention Type DEVICE

CPAP-treatment

night time CPAP-mask ventilation

Intervention Type DEVICE

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* AGE 18-85 years,
* NIH-SS 2-20 points,
* NIH-SS subitem 1a \<=1.

Exclusion Criteria

* Modified Rankin Scale Score \>=2 on admission
* primary intubation,
* Congestive heart failure (NYHA \>=3),
* respiratory insufficiency
* recurrent vomiting
* absence of gag reflex,
* participation in another RCT

for the ultrasound sub-study

* absence of temporal bone window for insonation
* stenosis or occlusion of major brain supplying arteries interfering with normal blood flow
Minimum Eligible Age

18 Years

Maximum Eligible Age

85 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

New Health Sciences, Inc.

INDUSTRY

Sponsor Role collaborator

Rubel GmbH, Heiligenhaus, Germany

UNKNOWN

Sponsor Role collaborator

University Hospital Muenster

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

University_Hospital_Muenster

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Darius G Nabavi, MD

Role: PRINCIPAL_INVESTIGATOR

University Hospital Muenster

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

University_Hospital_Muenster

Münster, , Germany

Site Status

Countries

Review the countries where the study has at least one active or historical site.

Germany

References

Explore related publications, articles, or registry entries linked to this study.

Turkington PM, Bamford J, Wanklyn P, Elliott MW. Prevalence and predictors of upper airway obstruction in the first 24 hours after acute stroke. Stroke. 2002 Aug;33(8):2037-42. doi: 10.1161/01.str.0000023576.94311.27.

Reference Type BACKGROUND
PMID: 12154259 (View on PubMed)

Bassetti C, Aldrich MS, Quint D. Sleep-disordered breathing in patients with acute supra- and infratentorial strokes. A prospective study of 39 patients. Stroke. 1997 Sep;28(9):1765-72. doi: 10.1161/01.str.28.9.1765.

Reference Type BACKGROUND
PMID: 9303023 (View on PubMed)

Iranzo A, Santamaria J, Berenguer J, Sanchez M, Chamorro A. Prevalence and clinical importance of sleep apnea in the first night after cerebral infarction. Neurology. 2002 Mar 26;58(6):911-6. doi: 10.1212/wnl.58.6.911.

Reference Type BACKGROUND
PMID: 11914407 (View on PubMed)

Minnerup J, Ritter MA, Wersching H, Kemmling A, Okegwo A, Schmidt A, Schilling M, Ringelstein EB, Schabitz WR, Young P, Dziewas R. Continuous positive airway pressure ventilation for acute ischemic stroke: a randomized feasibility study. Stroke. 2012 Apr;43(4):1137-9. doi: 10.1161/STROKEAHA.111.637611. Epub 2011 Dec 22.

Reference Type DERIVED
PMID: 22198979 (View on PubMed)

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

NHSi2005-iCPAPAPNEASTROKE-001

Identifier Type: -

Identifier Source: secondary_id

UKM-SL-70234

Identifier Type: -

Identifier Source: secondary_id

IMF-DZ-110413

Identifier Type: -

Identifier Source: org_study_id